Hippo Pathway in Neurodegeneration

Migration, Crosslink

📖

Hippo Pathway in Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:50 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-hippo-pathway-neurodegen

📖 Wiki Page

mechanism1441 wordssynced 2026-04-02

Hippo Pathway in Neurodegeneration

Overview

Hippo Pathway In Neurodegeneration plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

The Hippo signaling pathway is a highly conserved kinase cascade that regulates organ size, cell proliferation, and tissue homeostasis. Originally discovered in Drosophila, this pathway has emerged as a critical regulator of neuronal survival, stem cell function, and neurodegeneration[@metabolic].

Introduction of the Hippo Pathway

Core Pathway Components

| Component | Function | Neurodegeneration Relevance |
|-----------|----------|---------------------------|
| MST1/2 (Hippo) | Kinase, activates LATS1/2 | Pro-apoptotic in [neurons](/cell-types/neurons) |
| SAV1 | Scaffold protein | Forms complex with MST1/2 |
| LATS1/2 | Kinase, phosphorylates YAP/TAZ | Tumor suppressor |
| MOB1A/B | Scaffold for LATS | Essential for kinase activity |
| YAP/TAZ | Transcriptional co-activators | Pro-survival when active |
| TEAD1-4 | Transcription factors | Partner YAP/TAZ |

Pathway Regulation

...

Hippo Pathway in Neurodegeneration

Overview

Hippo Pathway In Neurodegeneration plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

The Hippo signaling pathway is a highly conserved kinase cascade that regulates organ size, cell proliferation, and tissue homeostasis. Originally discovered in Drosophila, this pathway has emerged as a critical regulator of neuronal survival, stem cell function, and neurodegeneration[@metabolic].

Introduction of the Hippo Pathway

Core Pathway Components

| Component | Function | Neurodegeneration Relevance |
|-----------|----------|---------------------------|
| MST1/2 (Hippo) | Kinase, activates LATS1/2 | Pro-apoptotic in [neurons](/cell-types/neurons) |
| SAV1 | Scaffold protein | Forms complex with MST1/2 |
| LATS1/2 | Kinase, phosphorylates YAP/TAZ | Tumor suppressor |
| MOB1A/B | Scaffold for LATS | Essential for kinase activity |
| YAP/TAZ | Transcriptional co-activators | Pro-survival when active |
| TEAD1-4 | Transcription factors | Partner YAP/TAZ |

Pathway Regulation

Mermaid diagram (expand to render)

Hippo Pathway in Alzheimer's Disease

Tau Pathology Connection

The Hippo pathway intersects with Alzheimer's disease through multiple mechanisms:

MST1 activation — [Tau](/proteins/tau) pathology activates MST1 kinase

YAP/TAZ sequestration — Phosphorylated YAP/TAZ trapped in cytoplasm

Reduced pro-survival signaling — Decreased TEAD target gene expression

Synaptic dysfunction — YAP regulates synaptic protein expression

Key Findings

[TAU](/genes/mapt) pathology activates MST1 in neurons
MST1 phosphorylates and degrades TAZ
YAP nuclear translocation reduced in AD brain
TEAD target genes downregulated in AD

Therapeutic Implications

| Target | Approach | Status |
|--------|----------|--------|
| MST1 inhibitors | Block pro-apoptotic kinase | Preclinical |
| YAP activators | Promote nuclear localization | Investigational |
| TEAD agonists | Enhance pro-survival transcription | Early research |

Hippo Pathway in Parkinson's Disease

Dopaminergic Neuron Vulnerability

The Hippo pathway plays a critical role in dopaminergic neuron survival:

MST1 activation — Environmental toxins activate MST1

YAP degradation — Reduced pro-survival signaling

[α-Synuclein](/proteins/alpha-synuclein) interaction — α-Syn affects Hippo pathway components

Mitochondrial stress — MST1 mediates stress response

Key Findings

[LRRK2](/genes/lrrk2) mutations affect Hippo pathway
[PINK1](/genes/pink1) deficiency dysregulates MST1
YAP nuclear localization reduced in PD brain
MST1 mediates 6-OHDA-induced apoptosis

Cross-Pathway Interactions

[mTOR pathway](/mechanisms/mtor-signaling-neurodegeneration) — intersects with Hippo
[Autophagy](/mechanisms/autophagy) — YAP regulates autophagic genes
[Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction-neurodegeneration) — stress activates MST1

Hippo Pathway in Amyotrophic Lateral Sclerosis

Motor Neuron Vulnerability

ALS shows specific Hippo pathway dysregulation:

MST1 hyperactivation — In motor neurons

YAP cytoplasmic retention — Reduced survival signaling

[TDP-43](/mechanisms/tdp-43-proteinopathy) pathology — Affects Hippo pathway gene expression

FUS mutations — Disrupt Hippo pathway regulation

Key Findings

MST1 activation in ALS motor neurons
Reduced YAP/TAZ nuclear localization
TEAD-dependent transcription impaired
Cross-talk with [ER stress](/mechanisms/er-stress-neurodegeneration) pathways

Hippo Pathway and Neuroinflammation

Microglial Hippo Signaling

The Hippo pathway regulates microglial function:

YAP in [microglia](/cell-types/microglia-neuroinflammation) — Controls inflammatory gene expression

MST1 regulation — Mediates cytokine-induced apoptosis

Cross-talk with [NF-κB](/entities/nf-kb) — Coordinates inflammatory response

Therapeutic Targeting

Hippo pathway modulators may reduce neuroinflammation:

YAP agonists reduce microglial activation
MST1 inhibitors protect neurons from inflammatory death

YAP/TAZ in Neuroprotection

Mechanistic Insights

YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif) serve as key transcriptional effectors of the Hippo pathway with significant neuroprotective functions[@hansen2021]:

Pro-survival gene expression: YAP/TAZ translocate to the nucleus and activate genes promoting neuronal survival

Anti-apoptotic signaling: Direct activation of Bcl-2 family genes

Metabolic regulation: Enhancement of mitochondrial function

Autophagy modulation: Regulation of autophagic flux

YAP Nuclear Localization

In neurodegeneration, YAP nuclear localization is compromised:

AD: Reduced nuclear YAP in prefrontal cortex[@zhao2022]
PD: α-Synuclein accumulation prevents YAP nuclear translocation[@yang2023]
ALS: TDP-43 pathology disrupts YAP/TAZ signaling

Therapeutic Activation

Strategies to restore YAP/TAZ activity include:

Pharmacological activators: Small molecules promoting nuclear localization
Viral gene therapy: AAV-mediated YAP delivery
Kinase inhibitors: MST1/2 inhibitors to prevent YAP phosphorylation

Ferroptosis Connection

New Insights

Recent research has revealed a critical connection between Hippo signaling and ferroptosis, a form of iron-dependent cell death[@wang2024]:

MST1 promotes ferroptosis: Activated MST1 enhances lipid peroxidation

YAP protects against ferroptosis: Nuclear YAP promotes antioxidant gene expression

Lats1/2 ablation paradoxically protective: Loss of Lats1/2 increases neuronal resilience against ferroptosis through unphosphorylated YAP[@inhibition]

Therapeutic Implications

YAP activators may reduce ferroptotic cell death
Ferroptosis inhibitors may act partly through Hippo pathway modulation
Combination approaches targeting both pathways show promise

Molecular Mechanisms in Detail

MST1 Kinase Signaling

MST1 (Mammalian STE20-like protein kinase 1) is a central mediator of stress-induced neuronal death[@uhl2020]:

Activation triggers:

Oxidative stress
Mitochondrial dysfunction
DNA damage
Aβ toxicity
α-Synuclein pathology

Downstream targets:

FOXO transcription factors
p53-dependent apoptosis
JNK pathway activation
Autophagy regulation

LATS1/2 Kinase Function

LATS1/2 (Large tumor suppressor kinases) phosphorylate YAP/TAZ:

Phosphorylation sites: YAP Ser127, TAZ Ser89
Nuclear export: Phosphorylated YAP/TAZ retained in cytoplasm
Degradation: Subsequent proteasomal degradation

YAP/TAZ Transcriptional Partners

| Partner | Function | Neurodegeneration Relevance |
|---------|----------|-----------------------------|
| TEAD1-4 | Pro-survival gene activation | Reduced in AD |
| SMADs | TGF-β signaling | Altered in PD |
| p73 | Apoptosis regulation | Impaired in ALS |
| Runx1 | Differentiation | Dysregulated |

Therapeutic Strategies

Pharmacological Approaches

| Compound | Target | Mechanism | Development Stage |
|----------|--------|-----------|-------------------|
| Xmu-mp-1 | MST1 | Kinase inhibitor | Preclinical[@xmump] |
| Verteporfin | YAP-TEAD | Interaction inhibitor | Research |
| CBL-0137 | YAP | Nuclear translocation | Preclinical |
| Dexamethasone | MST1 | Kinase modulation | Preclinical |

Gene Therapy Approaches

Viral delivery of YAP/TAZ
MST1 siRNA
TEAD expression constructs

Clinical Development

Several compounds are in various stages of development[@chiang2024]:

| Agent | Target | Stage | Indication |
|-------|--------|-------|------------|
| Xmu-mp-1 | MST1 | Preclinical | AD |
| Verteporfin | YAP-TEAD | Research | PD |
| CBL-0137 | YAP | Preclinical | ALS |

Challenges and Considerations

Blood-brain barrier penetration
Target specificity
Off-target effects
Optimal delivery methods

Cross-Pathway Interactions

mTOR-Hippo Axis

The Hippo pathway intersects with mTOR signaling in neurodegeneration:

mTOR regulates Hippo: Active mTOR inhibits LATS1/2

Hippo affects mTOR: YAP/TAZ influence mTORC1 activity

Therapeutic targeting: Dual inhibition shows synergy

Autophagy Connection

YAP/TAZ regulate autophagic genes:

TFEB activation: YAP promotes TFEB nuclear translocation
Lysosomal function: Enhanced autolysosome formation
α-Synuclein clearance: Improved autophagy of pathological proteins

Mitochondrial Dynamics

Hippo pathway influences mitochondrial function:

MST1 inhibits PGC-1α: Reduces mitochondrial biogenesis
YAP promotes mitophagy: Through BNIP3L expression
Energy metabolism: Altered ATP production

Research Pipeline and Future Directions

Ongoing Clinical Trials

YAP modulators in preclinical development
MST1 inhibitors in early-phase trials
Gene therapy approaches for YAP delivery

Biomarker Development

YAP nuclear localization as biomarker
MST1 activity measurements
YAP target gene expression profiling

Combination Therapies

YAP activators with antioxidants
MST1 inhibitors with ferroptosis modulators
Gene therapy with small molecules

References

[Qin X, et al., Xmu-mp-1 attenuates streptozotocin-induced neurotoxicity in SH-SY5Y cells (2024)](https://pubmed.ncbi.nlm.nih.gov/41686328/)

[Wang L, et al., A metabolic cell death program downstream of SARM1 (2024)](https://pubmed.ncbi.nlm.nih.gov/41364765/)

[Xie Y, et al., Inhibition of Hippo Signaling Through Ablation of Lats1 and Lats2 Protects Against Cognitive Decline in 5xFAD Mice (2024)](https://pubmed.ncbi.nlm.nih.gov/40923675/)

[Zhang M, et al., An unrecognized mechanism of self-protection in degenerating neurons mediated by astrocytic YAP (2024)](https://pubmed.ncbi.nlm.nih.gov/40860154/)

[Li W, et al., Neuroprotective role of Hippo signaling by microtubule stability control (2024)](https://pubmed.ncbi.nlm.nih.gov/40178516/)

[Uhl M, et al., Hippo pathway kinases in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32829482/)

[Hansen M, et al., YAP/TAZ signaling in neuronal stress response and neurodegenerative disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34471275/)

[Zhao L, et al., Hippo pathway dysregulation in Alzheimer's disease brain (2022)](https://pubmed.ncbi.nlm.nih.gov/35642093/)

[Deggau M, et al., Targeting MST1 kinase in neurodegenerative disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37532456/)

[Chiang AC, et al., Modulators of YAP/TAZ activity as neuroprotective agents (2024)](https://pubmed.ncbi.nlm.nih.gov/38789234/)

[Yang C, et al., Hippo pathway in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37433719/)

[Gupta P, et al., Hippo pathway kinases as therapeutic targets in ALS (2024)](https://pubmed.ncbi.nlm.nih.gov/38264018/)

[Liu L, et al., YAP-mediated neuroprotection in tauopathies (2022)](https://pubmed.ncbi.nlm.nih.gov/35659911/)

[Wang J, et al., Ferroptosis and the Hippo pathway (2024)](https://pubmed.ncbi.nlm.nih.gov/39012789/)

Pathway Diagram

The following diagram shows the key molecular relationships involving Hippo Pathway in Neurodegeneration discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

mechanisms-hippo-pathway-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-hippo-pathway-neurodegeneration
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-0d880ba9d999
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-hippo-pathway-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

567

Outgoing

774

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Hippo Pathway in Neurodegeneration

Hippo Pathway in Neurodegeneration

Overview

Introduction of the Hippo Pathway

Core Pathway Components

Pathway Regulation

Hippo Pathway in Neurodegeneration

Overview

Introduction of the Hippo Pathway

Core Pathway Components

Pathway Regulation

Hippo Pathway in Alzheimer's Disease

Tau Pathology Connection

Key Findings

Therapeutic Implications

Hippo Pathway in Parkinson's Disease

Dopaminergic Neuron Vulnerability

Key Findings

Cross-Pathway Interactions

Hippo Pathway in Amyotrophic Lateral Sclerosis

Motor Neuron Vulnerability

Key Findings

Hippo Pathway and Neuroinflammation

Microglial Hippo Signaling

Therapeutic Targeting

YAP/TAZ in Neuroprotection

Mechanistic Insights

YAP Nuclear Localization

Therapeutic Activation

Ferroptosis Connection

New Insights

Therapeutic Implications

Molecular Mechanisms in Detail

MST1 Kinase Signaling

LATS1/2 Kinase Function

YAP/TAZ Transcriptional Partners

Therapeutic Strategies

Pharmacological Approaches

Gene Therapy Approaches

Clinical Development

Challenges and Considerations

Cross-Pathway Interactions

mTOR-Hippo Axis

Autophagy Connection

Mitochondrial Dynamics

Research Pipeline and Future Directions

Ongoing Clinical Trials

Biomarker Development

Combination Therapies

See Also

References

Pathway Diagram

💬 Discussion